linkedin

Press Releases

Samsung BIO Insight

A Strategic Roadmap for Sustainable Growth - Samsung Biologics at J.P. Morgan Healthcare Conference 2022

A Strategic Roadmap for Sustainable Growth 

- Samsung Biologics at J.P. Morgan Healthcare Conference 2022

 

 

At the 40th Annual J.P. Morgan Healthcare Conference, which was held virtually from January 10th to 13th, Samsung Biologics’ CEO John Rim shared the company’s sustainable growth plan, consolidating its vision and business goals for 2022. 

 

During the main track presentation, which Samsung Biologics was invited to in 6 consecutive years, Rim addressed the three core pillars for the company’s multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint.

 

With the company aims to evolve as the top biopharmaceutical company, Rim outlined the key growth drivers for 2022 and here are some of the key highlights from the presentation. 

 

 

Key achievements of 2021

 

Key achievements of 2021

Key achievements of 2021

Achievements of 2021

  • Accumulated a total of 61 CMO contracts(As of thira quarter of 2021)
  • Launched CDO process platform, S-CellerateTM (Offering expedited process for the development and commercialization of monoclonal antibodies)
  • Marked record-high financial results(Accumulative revenue of KRW 1.24 trillion and operating profit of KRW 408.5 billion as of third quarter of 2021)
  • Expanded mRNA services offerings(Signing mRNA DP contract, adding mRNA DS manufacturing suite, and securing additional land for the building of MMP)
  • Launched ESG management system(lssuing first annual sustainability report, joining DOW jonse Sustainability World index(DJSI), participating in Sustainable Markets Initiative Task Force)

*Multi-Modal Plant 

*Korea Corporate Governance Service

*Dow Jones Sustainability ‘World’ Index

*Sustainable Market Initiative

 


Business goals and vision for 2022

 

1) Expanded manufacturing capacity


Expanded manufacturing capacity

Expanded manufacturing capacity

  • Plant 1(30,000L)
  • Plant 2(154,000L)
  • Plant 3(180,000L)
  • Plant 4(256,000L)

  Plant 4 partially operational (Q4 2022) 

 Secure additional sites within Songdo for Bio Campus II

 

 

2) Advancements in business portfolio


Advancements in business portfolio

Advancements in business portfolio

mAb/Fusion Protein

Cell/Gene Therapy Vaccine, Viral Vector

mRNA

mAb/Fusion Protein

+

Open Innovation

  Successfully process mRNA DS cGMP Ready (Q2 2022)

 Groundbreaking of Plant 5, which will offer multi-modal products including cell & gene therapies  

and next-gen vaccines utilizing mRNA, pDNA and viral vectors, all at a single site  

 Establish plans for Open Innovation Center 

 

 

3) Greater global footprint


Greater global footprint
 

 Expand overseas, additionally to San Francisco R&D Center

  

 

Expand overseas, additionally to San Francisco R&D Center

 

 

 

Related contents

 

Press Release Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference

News BrieJP Morgan Healthcare Conference (Audio Link)

YouTube The Future of BioPharma: Plant 4

ESG Sustainability Report 2021

 

 

 A Strategic Roadmap for Sustainable Growth

- Samsung Biologics at J.P. Morgan Healthcare Conference 2022

 

  

At the 40th Annual J.P. Morgan Healthcare Conference, which was held virtually from January 10th to 13th, Samsung Biologics’ CEO John Rim shared the company’s sustainable growth plan, consolidating its vision and business goals for 2022. 

 

During the main track presentation, which Samsung Biologics was invited to in 6 consecutive years, Rim addressed the three core pillars for the company’s multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint.

 

With the company aims to evolve as the top biopharmaceutical company, Rim outlined the key growth drivers for 2022 and here are some of the key highlights from the presentation. 

 

 

Key achievements of 2021

 

Key achievements of 2021

Key achievements of 2021

Achievements of 2021

  • Accumulated a total of 61 CMO contracts(As of thira quarter of 2021)
  • Launched CDO process platform, S-CellerateTM (Offering expedited process for the development and commercialization of monoclonal antibodies)
  • Marked record-high financial results(Accumulative revenue of KRW 1.24 trillion and operating profit of KRW 408.5 billion as of third quarter of 2021)
  • Expanded mRNA services offerings(Signing mRNA DP contract, adding mRNA DS manufacturing suite, and securing additional land for the building of MMP)
  • Launched ESG management system(lssuing first annual sustainability report, joining DOW jonse Sustainability World index(DJSI), participating in Sustainable Markets Initiative Task Force)

*Multi-Modal Plant 

*Korea Corporate Governance Service

*Dow Jones Sustainability ‘World’ Index

*Sustainable Market Initiative

 


Business goals and vision for 2022

 

1) Expanded manufacturing capacity


Expanded manufacturing capacity

Expanded manufacturing capacity

  • Plant 1(30,000L)
  • Plant 2(154,000L)
  • Plant 3(180,000L)
  • Plant 4(256,000L)

  Plant 4 partially operational (Q4 2022) 

 Secure additional sites within Songdo for Bio Campus II

 

 

2) Advancements in business portfolio


Advancements in business portfolio

Advancements in business portfolio

mAb/Fusion Protein

Cell/Gene Therapy Vaccine, Viral Vector

mRNA

mAb/Fusion Protein

+

Open Innovation

  Successfully process mRNA DS cGMP Ready (Q2 2022)

 Groundbreaking of Plant 5, which will offer multi-modal products including cell & gene therapies  

and next-gen vaccines utilizing mRNA, pDNA and viral vectors, all at a single site  

 Establish plans for Open Innovation Center 

 

 

3) Greater global footprint


Greater global footprint
 

 Expand overseas, additionally to San Francisco R&D Center

  

 

Expand overseas, additionally to San Francisco R&D Center

 

 

 

Related contents

 

Press Release Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference

News BrieJP Morgan Healthcare Conference (Audio Link)

YouTube The Future of BioPharma: Plant 4

ESG Sustainability Report 2021

 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved